It’s remarkable news on the health-care front, as Israeli-based Kalytera Therapeutics Inc (TSX-Venture:KALY) Kalytera Therapeutics, Inc. announced additional positive interim data from its ongoing Phase 2 clinical study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”) following bone marrow transplants.
Kalytera announced Tuesday that, during the six weeks following a similar announcement in December, no additional patients have developed GVHD of any grade.
Said CEO Robert Farrell declared, “These interim results are encouraging. Our goal is to diminish the risk of developing GVHD that cancer patients face when choosing to undergo a bone marrow transplant procedure, and we believe that CBD has the potential to become the first pharmaceutical to be approved for prevention of GVHD.”
Most patients receiving bone marrow transplants are patients with various forms of blood cancers, such as leukemia, lymphoma or multiple myeloma. Bone marrow transplantation has boosted survival rates for some blood cancers from nearly zero to more than 85%.
However, recipients of such transplants are at high risk of developing acute GVHD, a life-threatening complication that occurs when the transplanted donor cells attack the patient’s organs, including the skin, GI tract, liver, lungs, and eyes.
Kalytera, which trades on the Venture Exchange under the symbol KALY, had gained a penny in price, or 12.5%, to nine cents late Tuesday morning, on volume of 1.8 million shares.